COMPASS Pathways plc

NASDAQ•CMPS

CEO: Mr. Kabir Kumar Nath M.A., M.B.A.

Sector: Healthcare

Industry: Medical - Care Facilities

Listing Date: 2020-09-18

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Contact Information

33 Broadwick Street, London, W1F 0DQ, United Kingdom

44-71-6676-6461

compasspathways.com

Market Cap

$1.13B

P/E (TTM)

-7.3

29.4

Dividend Yield

52W High

$12.24

52W Low

$2.25

52W Range

96%

Rank65Top 96.0%

1.6

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Weak • 1.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q1 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

$0.70+0.00%

4-Quarter Trend

FCF

-$47.94M+0.00%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Phase 3 TRD Trial Success COMP005 trial met primary endpoint (p<0.001); planning rolling NDA submission for COMP360 treatment.

Balance Sheet Asset Growth Total assets reached $255.6M USD, up $41.9M since December 31, 2024, driven by financing proceeds.

Cash Position Maintained Cash and equivalents totaled $185.9M USD, expected to fund operating expenses into 2027 based on current estimates.

Financing Provided Capital Net cash provided by financing activities totaled $140.5M USD for the nine months ended September 30, 2025.

Risk Factors

Operating Losses Significantly Widened Nine-month net loss increased to $(194.0)M USD, up $(82.2)M compared to the prior year period.

Large Warrant Liability Balance Total warrant liabilities recorded on balance sheet reached $165.6M USD as of September 30, 2025.

Increased Operating Cash Burn Net cash used in operating activities rose to $(119.5)M USD, reflecting higher R&D and operational spending.

Clinical Development Uncertainty Success depends entirely on COMP360 regulatory approval; clinical delays or negative data risk material harm.

Outlook

Advance TRD and PTSD Programs Continue advancing Phase 3 TRD program while initiating late-stage development for the PTSD indication.

Prepare for NDA Submission Plan to submit rolling NDA proposal to FDA for COMP360 TRD treatment based on recent discussions.

Increase Commercialization Spending Expect significant future increases in G&A expenses preparing for commercial operations, subject to Phase 3 data.

Substantial Future Funding Needs Future funding requirements remain substantial to support operations and commercialization efforts beyond 2027.

Peer Comparison

Revenue (TTM)

CYH

$21.48B

+69.8%

AMN

$3.42B

+19.9%

EHAB

$1.06B

+3.2%

Gross Margin (Latest Quarter)

ATXS

100.0%

+0.0pp

GOSS

98.6%

+0.0pp

PRTA

98.2%

-1198.3pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
KOD	$1.92B	-9.7	-253.8%	18.3%
KALV	$1.43B	-9.8	-1057.4%	45.2%
MLTX	$1.34B	-5.0	-85.6%	25.2%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Jul 30, 2026

EPS:-$0.39

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data